论文部分内容阅读
为了探讨替吉奥联合奥沙利铂对转移性三阴乳腺癌患者随机对照研究及对血清P53抗体(serum P53antibody,P53)、第十号染色体同源丢失性磷酸酶-张力蛋白基(phosphatase and tensin homolog deleted from chromosome ten,PTEN)的影响。将90例转移性三阴乳腺癌患者按系统随机化法分为对照组45例和观察组45例。对照组采用奥沙利铂135 mg/m~2+1 000 m L Glu,静脉滴注,每4周1次,行3个疗程的化疗。观察组在对照组的基础上加用替吉奥胶囊40~60 mg/次,2次/d,每4周1次进行治疗,行3个疗程的化疗。比较2组患者的治疗后的临床疗效、血清P53、PTEN及HIF-α水平及毒副作用。结果表明观察组的总有效率及控制率与对照组比较无明显差异(p>0.05),但观察组患者的稳定率(44.44%)明显高于对照组(22.22%)(p<0.05)。2组患者的P53、HIF-α指标与治疗前相比均明显降低(p<0.05),且观察组患者低于对照组(p<0.05);2组患者的PTEN水平与治疗前相比,均明显升高(p<0.05),且观察组高于对照组(p<0.05)。观察组患者不良反应发生率为11.11%与对照组的17.77%相比,无明显差异(p>0.05)。替吉奥联合奥沙利铂治疗转移性三阴乳腺癌疗效肯定,能改善患者血清P53、PTEN及HIF-α水平,且毒副反应小。
In order to investigate the randomized control study of TIGO combined with oxaliplatin in patients with metastatic triple negative breast cancer and its effect on the expression of serum P53 antibody (P53), phosphatase at chromosome 10 tensin homolog deleted from chromosome ten, PTEN). Ninety patients with metastatic triple negative breast cancer were divided into control group (n = 45) and observation group (n = 45) according to systematic randomization method. The control group received oxaliplatin 135 mg / m 2 + 1 000 m L Glu intravenously once a week for 3 courses of chemotherapy. On the basis of the control group, the observation group was given Teggio capsules 40-60 mg twice daily for 3 weeks once a week for 3 cycles of chemotherapy. The clinical efficacy, serum P53, PTEN and HIF-α levels and toxicity were compared between the two groups. The results showed that the total effective rate and control rate in the observation group had no significant difference compared with the control group (p> 0.05). However, the stability rate in the observation group was significantly higher than that in the control group (44.44% vs 22.22%, p <0.05). The levels of P53 and HIF-α in the two groups were significantly lower than those before treatment (p <0.05), and the patients in the observation group were lower than those in the control group (p <0.05). The PTEN levels in the two groups were significantly lower than those before treatment Were significantly higher (p <0.05), and the observation group was higher than the control group (p <0.05). The incidence of adverse reactions in the observation group was 11.11% compared with 17.77% in the control group, there was no significant difference (p> 0.05). For the treatment of metastatic triple negative breast cancer with geggio and oxaliplatin, the positive rates of P53, PTEN and HIF-α in serum are improved, and the side effects are small.